Loading study record…
The aim of this observational study is to evaluate the effects of cannabis extract Avextra 10/10 solution on pain, fatigue, sleep, and quality of life among patients affected by fibromyalgia (FM) syndrome. The main question it aims to answer is: Does cannabis extract have a positive effect on pain after 12 weeks in these patients? Participants diagnosed from FM will be evaluated and will fill survey about their pain, fatigue, sleep, anxiety, depression and quality of life at baseline, 4 weeks, 8 weeks and 12 weeks after the initiation of cannabis extract Avextra 10/10 solution.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2024-12-24
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Fibromyalgia (FM) is a chronic condition characterized by widespread pain, mechanical hyperalgesia, fatigue, sleep disturbances, psychological and cognitive impairments, mood changes, headaches, migraines, and gastrointestinal symptoms. Despite its recognition as a medical condition with diagnostic criteria and severity scales, its exact causes and effective treatment remain unclear. FM significantly impacts patients' quality of life and poses a societal burden due to high direct and indirect costs. Cannabis-based treatments have gained attention for FM symptom management. In Italy, therapeutic cannabis has been legal since 2013 and may be prescribed when conventional treatments fail or cause intolerable side effects. Its primary components, tetrahydrocannabinol (THC) and cannabidiol (CBD), interact with cannabinoid receptors to potentially provide pain relief, anti-inflammatory effects, and mood stabilization. The study aims to evaluate the efficacy of the standardized cannabis extract Avextra 10/10 (10 mg/mL THC and 10 mg/mL CBD) for FM treatment. Objectives Primary objective: -Assess the extract's impact on pain after 12 weeks. Secondary objective: * Evaluate the clinical effect of cannabis extract Avextra 10/10 solution on fatigue, sleep, anxiety and depression after 4, 8 and 12 weeks among patients affected by FM * Evaluate the clinical effect of cannabis extract Avextra 10/10 solution on pain after 4 and 8 weeks among patients affected by FM. * Evaluate the effect of cannabis extract Avextra 10/10 solution on the quality of life at 4, 8 and 12 weeks among patients affected by FM. * Describe any adverse events or the principal reasons of drug discontinuation. Design and Methods This is a monocentric observational prospective study in which patients with FM who undertake cannabis therapy with cannabis extract Avextra 10/10 solution will consecutively be recruited. Population: The inclusion criteria are: * Patients with a diagnosis of FM according to 2016 American College of Rheumatology Criteria \[2\]. * Patients with FM prescribed cannabis extract Avextra 10/10 solution after failure and/or intolerance of first- or second-line treatment. * Aged 18 years and older. * Able to fully understand and fill questionnaires. * Able to provide informed consent, according to requirements of local IRB/ethics committee. The exclusion criteria are: * Known history of pain not due to FM. * Patients who have not received stable therapy for pain, sleep disorders, or any psychiatric condition for at least 2 weeks. * Patients who are taking other types of medical cannabis besides Avextra 10/10 solution. * Concomitant diagnosis of other pathologies that could interfere with clinical judgment. * Psychiatric diagnosis according to DSM-V-TR All patients with FM will undergo a standard clinical assessment, at baseline and at the follow-up visits, as part of the routine clinical practice. After the baseline visit, corresponding to the appointment where medical cannabis is prescribed within two weeks before the undertake of cannabis extract, follow-up visits will be scheduled according to routine clinical practice as follow: * 15 days after the undertake of cannabis extract (T15) * 30 days after the undertake of cannabis extract (T30) * 60 days after the undertake of cannabis extract (T60) * 90 days after the undertake of cannabis extract (T90) * 6 months after the undertake of cannabis extract. All patients with FM will undergo a standard clinical assessment, at baseline and at the follow-up visits, as part of the routine clinical practice. Data collected from participants during clinical evaluations at baseline visit will include: * Demographic data: age, gender, BMI, residence * Educational qualification * Occupational status * Age at menopause (if applicable) * Current medication * Comorbidities * Symptom duration * Age at FM diagnosis * Number of sure tender point * Smoke status * Physical activity Data collected from participants during clinical evaluations at follow-up visit will include: * Number of sure tender point * Smoke status * Physical activity * Efficacy or side effects of cannabis extract * Discontinuation of cannabis extract Conclusion The study seeks to establish the feasibility and clinical effects of a standardized cannabis extract for FM, addressing a critical gap in treatment strategies. Further research is needed to validate its efficacy and optimize FM management.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
No structured intervention was reported.
Eligibility
Patients afferent to IRCCS Ospedale Galeazzi Sant- Ambrogio in Milan (Italy) with FIbromyalgia Syndrome who will start therapy with cannabis extract Avextra 10/10.
primary outcomes
Time frame: 12 weeks
The primary endpoint is based on a comparative analysis between the Visual Analogic Scale (VAS) score reported before cannabis extract Avextra 10/10 solution and after 12 weeks of therapy. VAS will use a 100 mm pain line where 0 represents "no pain at all" and 100 is "maximum pain ever experienced".
secondary outcomes
Time frame: 4, 8 and 12 weeks
Pittsburgh sleep quality index (PSQI) consists of 19 self-rated questions and 5 questions rated by a bed partner or roommate (if applicable). The self-rated items are organized into seven component scores: * Subjective Sleep Quality: Perceived sleep quality overall. * Sleep Latency: Time taken to fall asleep. * Sleep Duration: Total hours of actual sleep per night. * Habitual Sleep Efficiency: Ratio of actual sleep to time spent in bed. * Sleep Disturbances: Frequency of problems such as waking up during the night. * Use of Sleep Medication: Frequency of use of sleeping pills or aids. * Daytime Dysfunction: Impact of poor sleep on daily activities, such as feeling tired or having difficulty concentrating. Each component is scored on a scale of 0 to 3, with higher scores indicating greater difficulty or poorer quality in that domain. The seven component scores are summed to yield a global score ranging from 0 to 21. A score of 5 or higher is generally indicative of poor sleep quality.
Time frame: 4, 8 and 12 weeks
The WPI lists 19 specific body areas that are grouped anatomically (upper and lower extremities (e.g., shoulders, arms, legs), axial regions (e.g., neck, lower back), cranial and chest regions (e.g., jaw, chest)). These regions are divided into the left and right sides of the body, where applicable. The patient indicates whether they have experienced pain in each of these areas during the past week. The response is binary (yes or no) for each area. Each body area where pain is reported is assigned a score of 1. The scores from all 19 areas are summed to produce the WPI total score, which ranges from 0 to 19.
Time frame: 4, 8 and 12 weeks
The Revised Fibromyalgia Impact Questionnaire (FIQR) is a validated, self-administered tool designed to measure the overall impact of fibromyalgia on a patient's daily life. The FIQR consists of 21 questions divided into three main domains: * Function (9 items): assesses the patient's ability to perform daily tasks and activities. * Overall Impact (2 items): measures the overall effect of fibromyalgia on the patient's life and how they perceive their condition. * Symptom Severity (10 items): covers common fibromyalgia symptoms. Each question is scored on a 0 to 10 scale, where 0 (No difficulty or symptoms) 10 (Extreme difficulty or worst symptoms). The scores from all three domains are combined to give a total FIQR score, ranging from 0 to 100
Time frame: 4,8,12 weeks
Describe any adverse events or the principal reasons of drug discontinuation.
Time frame: 4, 8 weeks
Description: The secondary endpoint is based on a comparative analysis between the Visual Analogic Scale (VAS) score reported before cannabis extract Avextra 10/10 solution and after 12 weeks of therapy. VAS will use a 100 mm pain line where 0 represents "no pain at all" and 100 is "maximum pain ever experienced".
Time frame: 4, 8, 12 weeks
The Functional Appreciation Scale (FAS) is a tool designed to assess an individual's overall functionality and their ability to perform daily activities. It evaluates the impact of a condition, such as fibromyalgia, on physical, psychological, and social aspects of functioning. The scale typically captures subjective perceptions of functional limitations, providing valuable insights into the patient's quality of life and the effectiveness of therapeutic interventions
Time frame: 4, 8, 12 weeks
The Symptom Severity Score (SSS) is a tool used to assess the severity of symptoms in conditions like fibromyalgia. It evaluates key symptoms, including fatigue, sleep disturbances, cognitive issues, and somatic complaints, on a scale typically ranging from 0 to 3 (none to severe). The total score reflects the overall symptom burden, helping to classify and monitor the condition's severity.
Publications